Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma

by NASDAQ Market News January 6, 2022

NASDAQ Market News
Click here to email author

Medical Isolation Gowns Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type ; Product Type ; End User, and Geography

Ayala Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

Ads